Literature DB >> 30411980

Inflammatory signature in lung tissues in patients with combined pulmonary fibrosis and emphysema.

William D Cornwell1,2, Cynthia Kim2, Alejandra C Lastra2, Chandra Dass3, Sudhir Bolla2, He Wang4, Huaqing Zhao5, Frederick V Ramsey5, Nathaniel Marchetti1,2, Thomas J Rogers1,2, Gerard J Criner1,2.   

Abstract

Background: The aetiology and inflammatory profile of combined pulmonary fibrosis and emphysema (CPFE) remain uncertain currently. Objective: We aimed to examine the levels of inflammatory proteins in lung tissue in a cohort of patients with emphysema, interstitial pulmonary fibrosis (IPF), and CPFE. Materials and methods: Explanted lungs were obtained from subjects with emphysema, IPF, CPFE, (or normal subjects), and tissue extracts were prepared. Thirty-four inflammatory proteins were measured in each tissue section.
Results: The levels of all 34 proteins were virtually indistinguishable in IPF compared with CPFE tissues, and collectively, the inflammatory profile in the emphysematous tissues were distinct from IPF and CPFE. Moreover, inflammatory protein levels were independent of the severity of the level of diseased tissue. Conclusions: We find that emphysematous lung tissues have a distinct inflammatory profile compared with either IPF or CPFE. However, the inflammatory profile in CPFE lungs is essentially identical to lungs from patients with IPF. These data suggest that distinct inflammatory processes collectively contribute to the disease processes in patients with emphysema, when compared to IPF and CPFE.

Entities:  

Keywords:  CPFE; Emphysema; IPF; chronic inflammation; inflammatory protein

Mesh:

Substances:

Year:  2018        PMID: 30411980      PMCID: PMC6509019          DOI: 10.1080/1354750X.2018.1542458

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  37 in total

1.  Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease.

Authors:  Marina Saetta; Margherita Mariani; Paola Panina-Bordignon; Graziella Turato; Cecilia Buonsanti; Simonetta Baraldo; Cinzia M Bellettato; Alberto Papi; Lorenzo Corbetta; Renzo Zuin; Francesco Sinigaglia; Leonardo M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2002-05-15       Impact factor: 21.405

2.  CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.

Authors:  Marie D Burdick; Lynne A Murray; Michael P Keane; Ying Ying Xue; David A Zisman; John A Belperio; Robert M Strieter
Journal:  Am J Respir Crit Care Med       Date:  2004-10-22       Impact factor: 21.405

3.  Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans.

Authors:  Fengrong Zuo; Naftali Kaminski; Elsie Eugui; John Allard; Zohar Yakhini; Amir Ben-Dor; Lance Lollini; David Morris; Yong Kim; Barbara DeLustro; Dean Sheppard; Annie Pardo; Moises Selman; Renu A Heller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

4.  Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor.

Authors:  G W Hoyle; J Li; J B Finkelstein; T Eisenberg; J Y Liu; J A Lasky; G Athas; G F Morris; A R Brody
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype.

Authors:  Lennart K A Lundblad; John Thompson-Figueroa; Timothy Leclair; Michael J Sullivan; Matthew E Poynter; Charles G Irvin; Jason H T Bates
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

6.  Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD.

Authors:  W I de Boer; J K Sont; A van Schadewijk; J Stolk; J H van Krieken; P S Hiemstra
Journal:  J Pathol       Date:  2000-04       Impact factor: 7.996

7.  Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics.

Authors:  A Capelli; A Di Stefano; I Gnemmi; P Balbo; C G Cerutti; B Balbi; M Lusuardi; C F Donner
Journal:  Eur Respir J       Date:  1999-07       Impact factor: 16.671

Review 8.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

9.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3.

Authors:  Dianhua Jiang; Jiurong Liang; Jennifer Hodge; Bao Lu; Zhou Zhu; Shuang Yu; Juan Fan; Yunfei Gao; Zhinan Yin; Robert Homer; Craig Gerard; Paul W Noble
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.

Authors:  S L Traves; S V Culpitt; R E K Russell; P J Barnes; L E Donnelly
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

View more
  4 in total

1.  Lung proteomic biomarkers associated with chronic obstructive pulmonary disease.

Authors:  Yu-Hang Zhang; Michael R Hoopmann; Peter J Castaldi; Kirsten A Simonsen; Mukul K Midha; Michael H Cho; Gerard J Criner; Raphael Bueno; Jiangyuan Liu; Robert L Moritz; Edwin K Silverman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-10-20       Impact factor: 5.464

Review 2.  Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?

Authors:  Tiago M Alfaro; Carlos Robalo Cordeiro
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

Review 3.  Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease.

Authors:  Joon Young Choi; Jin Woo Song; Chin Kook Rhee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-01-27

Review 4.  Dysregulated Cell Signaling in Pulmonary Emphysema.

Authors:  Chih-Ru Lin; Karim Bahmed; Beata Kosmider
Journal:  Front Med (Lausanne)       Date:  2022-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.